TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12568272
Drug: Auricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular therapy using magnetic pearls (Group C)
Study: 12568272
Drug: Auricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular therapy using Junci Medulla (Group A)
Study: 12568272
Drug: Auricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular therapy using Semen Vaccariae (Group B)
Study: 10792330
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment with low dose ethinyl oestradiol (0.05 microgram/kg/day)
Study: 10792330
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (OD) injections of GH (6 IU/m2/day)
Study: 10792330
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily (BID) injections of GH (6 IU/m2/day)
Study: 10792330
Drug: Post-GH treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-GH treatment with adult dosage of oestrogens
Study: 8814838
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy with epirubicin (20 mg/40 mL saline)
Study: 1495577
Drug: Antiepileptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic therapy using two standard anti-epileptic drugs
Study: 6519902
Drug: Ciclazindol (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclazindol (three different doses)
Study: 31268180
Drug: Epirubicin, cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin, cisplatin and capecitabine (ECX) chemotherapy with bevacizumab (B)
Study: 31268180
Drug: Epirubicin, cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin, cisplatin and capecitabine (ECX) chemotherapy without bevacizumab (B)
Study: 26728766
Drug: CHoBI7 intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHoBI7 intervention (handwashing with soap and water treatment for 7 days)
Study: 23795621
Drug: MoodGYM (computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoodGYM (computerized cognitive behavioural therapy)
Study: 22687889
Drug: Clarithromycin, amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, amoxicillin and omeprazole (CAO)
Study: 22687889
Drug: Levofloxacin, amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin, amoxicillin and omeprazole (LAO)
Study: 20438568
Drug: Limited shock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited shock wave therapy (SWT)
Study: 17642523
Drug: DHA 900
Normalized name: DHA
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DHA 900 mg monotherapy for 5 days
Study: 17642523
Drug: DHA 600
Normalized name: DHA
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DHA 600 mg + mefloquine [MQ] 750 mg combination regimen
Study: 11942956
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for patients with inoperable primary tumors.
Study: 29023915
Drug: OCA 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA 10 mg
Study: 29023915
Drug: OCA 50
Normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: OCA 50 mg
Study: 22578254
Drug: Psilocybin (215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (215 μg/kg) + Ketanserin (50 mg)
Study: 16491671
Drug: Acetaminophen consumers
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen consumers
Study: 9191511
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily beta‐blocker therapy (oral atenolol, 50 to 200 mg)
Study: 9191511
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily calcium channel blocker therapy (oral diltiazem 120 to 360 mg)
Study: 1888800
Drug: Benzodiazepine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine therapy
Study: 17225720
Drug: Topical 0.03%
Normalized name: tacrolimus topical 0.03% topical ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.03% tacrolimus
Study: 24463121
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (with medications and exercise prescription)
Study: 24463121
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (with medications only)
Study: 15608037
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (0.25 mg of cetrorelix daily starting on day 6 of stimulation)
Study: 15608037
Drug: Long GnRH
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long GnRH agonist protocol (600 microg of buserelin acetate daily starting in the mid-luteal phase of the preceding cycle)
Study: 12794818
Drug: leflunomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: leflunomide (100 mg/day for 3 days, then 10 mg/day or 20 mg/day thereafter)
Study: 1710395
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid infusion (BCAAs = 15.5%)
Study: 7425963
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily Beclomethasone dipropionate (BDP) treatment
Study: 7425963
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times daily Beclomethasone dipropionate (BDP) treatment
Study: 23839319
Drug: 0.05 mcg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mcg/kg/min (GROUP A)
Study: 23839319
Drug: 0.1 µg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 µg/kg/min (GROUP B)
Study: 22828481
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n=10)
Study: 15830983
Drug: Epidural Injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Injection of Steroids
Study: 10051289
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/d)
Study: 7670117
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy based on polymerase chain reaction (PCR) technique
Study: 1688039
Drug: Xamoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (200 mg bd orally for 1 month)
Study: 7259982
Drug: Desoximetasone emollient
Normalized name: Desoximetasone
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desoximetasone emollient cream 0.25% applied twice daily
Study: 7259982
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate 0.1% cream applied twice daily
Study: 7259982
Drug: Desoximetasone emollient
Normalized name: Desoximetasone
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desoximetasone emollient cream
Study: 23569140
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with pelvic floor exercises for 24 weeks
Study: 23569140
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (ultrasonography, short wave diathermy and lumbar strengthening exercises) for 24 weeks
Study: 15274384
Drug: Epoetin beta,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin beta, 30,000 IU per week in three divided doses, with iron supplementation when needed.
Study: 8010420
Drug: Hyperbaric lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric lidocaine 5% solution in a single bolus of 75 mg
Study: 8010420
Drug: Hyperbaric lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric lidocaine 2.5% solution in increments of 25 mg (maximum of three doses)
Study: 8010420
Drug: Titrated doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated doses of 50 mg (n = 15)
Study: 8010420
Drug: Titrated doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated doses of 75 mg (n = 15)
Study: 8010420
Drug: Titrated doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated doses (overall)
Study: 22151477
Drug: Vitamin/mineral supplement
Normalized name: NESTABS DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin/mineral supplement
Study: 2909593
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (adequate diet)
Study: 31296256
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of TGFβ blocking antibody fresolimumab (10 mg/kg)
Study: 31296256
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of TGFβ blocking antibody fresolimumab (1 mg/kg)
Study: 21146229
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg quarterly
Study: 21146229
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg quarterly
Study: 21146229
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg monthly
Study: 21146229
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg quarterly and 0.5 mg quarterly
Study: 14622685
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl with local heat applied for 4 hours and again for 1 hour at 24 hours (Session B)
Study: 14622685
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl without local heat (Session A)
Study: 14622685
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl with heat applied for 15 minutes at 12 and 16 hours (Session C)
Study: 14622685
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl without heat (Session A)
Study: 10890611
Drug: Control (ventilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ventilator therapy without inhaled nitric oxide)
Study: 6419710
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin
Study: 1702235
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin and graded compression stockings
Study: 21573819
Drug: Daily sulphate‐bicarbonate‐calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sulphate‐bicarbonate‐calcium mineral water bath
Study: 17307426
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg once daily
Study: 17307426
Drug: metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 850 mg twice daily
Study: 14985866
Drug: 99mTc-DTPA excretion
Normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 99mTc-DTPA excretion method
Study: 11794148
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg once daily, initiated postoperatively
Study: 11794148
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily, initiated preoperatively
Study: 9608824
Drug: Nasal administration
Normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal administration of fenoterol
Study: 9608824
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of beta2-agonists
Study: 9608824
Drug: Frequent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent administration of small doses of beta2-agonists
Study: 9356783
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug treatment during washout)
Study: 11545
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and Salazopyrin treatment postoperatively for 33 weeks
Study: 11545
Drug: No medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medical treatment postoperatively
Study: 28453348
Drug: Moist hot
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moist hot pack treatment
Study: 21619383
Drug: AZD1305 (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1305 (test dose 250 mg, evening dose 125 mg on day 1, maintenance dose 125 mg twice daily)
Study: 21619383
Drug: AZD1305 (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1305 (test dose 500 mg, placebo evening dose, maintenance dose 125 mg twice daily)
Study: 21619383
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo test and maintenance dose)
Study: 11069791
Drug: Supervised IPT
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised IPT (900 mg twice weekly for 6 months, Regimen A)
Study: 11069791
Drug: Unsupervised IPT
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised IPT (900 mg twice weekly for 6 months, Regimen B)
Study: 11069791
Drug: Unsupervised IPT
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised IPT (300 mg daily for 6 months, Regimen C)
Study: 9713652
Drug: Daily rhuIL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhuIL-2 therapy
Study: 9713652
Drug: Pulse rhuIL-2
Normalized name: DULSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse rhuIL-2 therapy
Study: 7767241
Drug: Monthly feedback
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly feedback with peer comparison
Study: 27155741
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus fulvestrant 500 mg
Study: 30157389
Drug: Emicizumab 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 1.5 mg/kg/week (group A)
Study: 30157389
Drug: Emicizumab 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 3.0 mg/kg every 2 weeks (group B)
Study: 19102241
Drug: Anesthetic modes
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic modes and reflex exposures in the complex therapy
Study: 19102241
Drug: Conventional complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional complex therapy (control group)
Study: 16078205
Drug: Levetiracetam (add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (add-on therapy, starting dose of 500 mg twice per day up to 50 mg/kg/day)
Study: 7566945
Drug: Acenocoumarol treatment
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocoumarol treatment for at least 2 years (duration of treatment: 75.0 ± 52 months)
Study: 7566945
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not treated by anticoagulant)
Study: 2255215
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (Nicolan)
Study: 348615
Drug: Mitomycin C,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin C, 0.8 mg/kg body weight intravenously, twice a week for 5 weeks after surgery
Study: 31014975
Drug: Patients identifying
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients identifying medications by name (brand name: 50%; generic: 21%)
Study: 28624340
Drug: Combination to
Normalized name: OCTINOXATE 30 mg in 1 mL / TITANIUM DIOXIDE 47 mg in 1 mL TOPICAL CREAM [Garnier Skin Renew Miracle Skin Perfector Combination to Oily Skin BB Broad Spectrum SPF 20 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination to Denosumab
Study: 21634303
Drug: Quercetin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin supplementation (1 g/day for 6 weeks)
Study: 18217149
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day clopidogrel
Study: 18217149
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day clopidogrel
Study: 11742194
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg + amoxicillin 1 g + clarithromycin 500 mg (EAC)
Study: 11742194
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + amoxicillin 1 g + clarithromycin 500 mg (OAC)
Study: 9580087
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g/8 h) plus Amikacin (15 mg/kg/day)
Study: 3315775
Drug: Oral ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral ribavirin (800-1600 mg/day for 7 days)
Study: 6725033
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment
Study: 26059103
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of 70 mg/kg bovine surfactant within 30 minutes after birth
Study: 26059103
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with surfactant therapy for established RDS
Study: 24032191
Drug: Abdominal acupuncture
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal acupuncture therapy
Study: 20447648
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both (Diet + Activity)
Study: 9321530
Drug: cA2 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 (10 mg/kg)
Study: 9321530
Drug: cA2 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 (20 mg/kg)
Study: 2070884
Drug: 360 degrees
Normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 degrees of peripheral circumferential treatment
Study: 2070884
Drug: Feeder vessel
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeder vessel treatment
Study: 6418191
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic supplementation
Study: 6418191
Drug: Fentanyl and
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl and Alfentanil (all doses)
Study: 6418191
Drug: Alfentanil (larger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (larger doses)
Study: 31958280
Drug: MTX 10
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 10 mg subcutaneously (s.c.) weekly, starting 2 weeks before adalimumab (W-2) and continuing weekly thereafter.
Study: 31958280
Drug: MTX 10
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 10 mg s.c. weekly (MTX+).
Study: 31958280
Drug: MTX co-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX co-treatment >W26.
Study: 23296186
Drug: dextroamphetamine (dAMPH)
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextroamphetamine (dAMPH) infusion (0.3mg/kg)
Study: 23296186
Drug: baseline dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline dopamine D2/3 receptor availability with [(123)I]IBZM SPECT
Study: 21788428
Drug: 0.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 μg LPS/kg BW (L75)
Study: 21788428
Drug: 1.50 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.50 μg LPS/kg BW (L150)
Study: 21788428
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 μg LPS/kg BW)
Study: 21788428
Drug: LPS (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS (0.75 μg and 1.50 μg)
Study: 15287454
Drug: Intracranial pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracranial pressure (ICP) targeted therapy
Study: 16696859
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alpha-2b and ribavirin (48 weeks treatment)
Study: 15548142
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (ASA) 0.5 mg/kg/day
Study: 3300276
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) plus liver directed radiotherapy (RT)
Study: 3300276
Drug: Less than
Normalized name: IgA less than or equal to 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less than full RT doses
Study: 23179507
Drug: Cognitive-behavioural play
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural play therapy (not performed)
Study: 23179507
Drug: Sham play
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham play therapy
Study: 18212498
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (Venofer(R), 100 mg iron, twice a week for 8 weeks, then once a week for another 4 weeks)